Loading
HBEGF (Proheparin-binding EGF-like growth factor) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. Required for normal cardiac valve formation and normal heart function. Promotes smooth muscle cell proliferation.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.95, genetic association 0.00, clinical 0.08).
In plain words · HBEGF (Proheparin-binding EGF-like growth factor) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
HBEGF (Proheparin-binding EGF-like growth factor) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. Required for normal cardiac valve formation and normal heart function.
No product in this corpus aims at HBEGF yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA HBEGF: RNA tissue enhanced (urinary bladder 120 nTPM); blood lineage group enriched (dendritic cells 2 nTPM, monocytes 2 nTPM); no normal tissue stained high; highest cancer staining melanoma (1 of 9 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas HBEGF tissue; Open Targets ENSG00000113070 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Higashiyama et al, Science, 1991, "A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF". Source.
Sources: HGNC HGNC:3059 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q99075 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000113070 (association with cancer (MONDO_0004992) 0.61; (GraphQL API, CC0))
Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. Required for normal cardiac valve formation and normal heart function. Promotes smooth muscle cell proliferation. May be involved in macrophage-mediated cellular proliferation. It is mitogenic for fibroblasts, but not endothelial cells. It is able to bind EGF receptor/EGFR with higher affinity than EGF itself and is a far more potent mitogen for smooth muscle cells than EGF. Location: Secreted, extracellular space; Cell membrane (UniProt). Locus 5q31.3 (HGNC).
RNA: tissue enhanced (urinary bladder 120 nTPM), detected in all normal tissues. Blood: group enriched (dendritic cells 2 nTPM, monocytes 2 nTPM).
No normal tissue stained high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"HBEGF" OR ABSTRACT:"HBEGF" OR TITLE:"heparin binding EGF like growth factor" OR ABSTRACT:"heparin binding EGF like growth factor" OR TITLE:"Proheparin-binding EGF-like growth factor" OR ABSTRACT:"Proheparin-binding EGF-like growth factor" OR TITLE:"HB-EGF" OR ABSTRACT:"HB-EGF" OR TITLE:"HEGFL" OR ABSTRACT:"HEGFL") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HBEGF, not a curated reading list.